Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464256 · ClinicalTrials.gov registry record · Phase 3
Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 533
- Enrollment target
NCT00464256 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 533 participants.
The verdict
NCT00464256, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 533 participants
- Enrollment target
Study Summary
The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period.
Interventions
- DRUG rimonabant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464256
The ClinicalTrials.gov registry entry for NCT00464256 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 533 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rimonabant is the first listed.
NCT00464256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464256 about?
NCT00464256 is a clinical study titled "Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation". The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of...
What is the current status of trial NCT00464256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2004-04. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00464256?
The interventions under investigation include: rimonabant (DRUG).
Who is sponsoring clinical trial NCT00464256?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.